Alcon AG vs Royal Caribbean Cruises Ltd — how do they compare? Alcon AG trades at $73.46 (market cap $36.44B), while Royal Caribbean Cruises Ltd trades at $307.61 (market cap $82.15B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 2.3× Alcon AG's market cap, and Royal Caribbean Cruises Ltd pays the higher dividend (1.63%). Which is the better fit depends on your goals.
| ALC | RCL | |
|---|---|---|
Market Cap | $36.44B | $82.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.12 | $365.84 |
52-Week Low | $62.02 | $246.71 |
Enterprise Value | $40.28B | $104.79B |
Dividend Yield | 0.48% | 1.63% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.63, up 2.53% today, with a bullish technical signal from moving averages and strong recent earnings beats. Revenue growth is steady, reaching $10.40B in 2025, though net income margin dipped to 5.92%. Positive news includes raised 2026 profit guidance and new product launches driving investor optimism.
The outlook is positive with a consensus price target of $86.67 implying 17.7% upside, supported by analyst buy ratings. Risks include elevated P/E of 57.52 and potential tariff impacts, but operational cash flow strength and strategic collaborations provide a solid foundation for growth.
Royal Caribbean (RCL) trades at $309.24, up 0.4% with a bullish technical signal. The company shows strong fundamental momentum with Q2 2026 EPS beating expectations at $4.21 vs. $3.98 estimate, and revenue growth accelerating from $8.8B in 2022 to $17.9B in 2025. Net income margin improved to 23.54% while ROE stands at 45.33%. Recent news highlights strong demand and record pricing for 2027 bookings, though geopolitical concerns have slightly tempered European outlook.
RCL presents a compelling growth story with robust earnings momentum and analyst consensus pointing to 11% upside to the $343.09 price target. Key risks include geopolitical impacts on European itineraries, elevated debt levels at $18.47B long-term, and capital-intensive fleet expansion. The stock's premium valuation at P/E 18.97 requires continued execution on growth targets to justify current levels.
Trailing returns across standard periods
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →